Articles related to COMBINATION THERAPY

In this study, dostarlimab combined with carboplatin-paclitaxel demonstrated a marked improvement in progression-free and overall survival among endometrial cancer patients, particularly those with genetic markers for dMMR and MSI-H.

In managing acute decompensated heart failure, optimizing loop diuretic therapy is pivotal; initial aggressive dosing tailored to urinary outputs can significantly improve patient outcomes.

In a recent phase 2–3 trial, nirmatrelvir–ritonavir did not significantly shorten the time to COVID-19 symptom resolution compared to placebo, yet it demonstrated a trend towards reduced hospitalization and death rates, emphasizing the importance of tailored treatment strategies.

The combination of ribociclib and a nonsteroidal aromatase inhibitor was associated with a notable improvement in invasive disease–free survival rates among early-stage, HR-positive, HER2-negative breast cancer patients, highlighting a significant advancement in the therapeutic landscape of this common malignancy.

Explore the latest advancement in NSCLC treatment: the FDA-approved amivantamab combo has demonstrated a significant leap in progression-free survival for patients with specific genetic mutations, reshaping the standard of care.

In the high-risk patient cohort, the combination of baricitinib and remdesivir not only demonstrated a significant reduction in mortality and progression to invasive mechanical ventilation but also showcased an enhanced recovery trajectory.